RG1662
RG1662 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
1
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
6 of 6 finished
0.0%
0 ended early
0
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
A Study of the Effect of RG1662 on Metformin in Healthy Volunteers
A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy Subjects
A Molecular and Functional Brain Imaging Study in Individuals With Down Syndrome and Healthy Controls Following Single Dose RG1662
Clinical Trials (6)
A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
A Study of the Effect of RG1662 on Metformin in Healthy Volunteers
A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy Subjects
A Molecular and Functional Brain Imaging Study in Individuals With Down Syndrome and Healthy Controls Following Single Dose RG1662
A Study of RG1662 in Individuals With Down Syndrome
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6